Navigation Links
FDA Approves Hyperopia Application for the MEL 80 Excimer Laser from Carl Zeiss Meditec
Date:3/28/2011

by change in sphere and cylinder of < 0.5 D.

Brief profile Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology suppliers. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials. The company creates innovative visualization solutions in the field of microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiation therapy. In the 2009/2010 (30 September) financial year, around 2,200 employees generated revenue of EUR 676 million.

The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. Thirty-five percent of Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and opto-electronics industry. Carl Zeiss offers innovative solutions for the future-oriented markets Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. In financial year 2009/2010, the Group generated revenue of around EUR 2.98 billion. From financial year 2010/2011 onwards, eyeglass lens manufacturer Carl Zeiss Vision shall be integrated as an autonomous business group (revenue of around EUR 880 million in financial year 2009/2010). The Carl Zeiss Group thus employs a workforce of around 24,000 worldwide, more than 10,000 of whom are based in Germany. Carl Zeiss AG, Oberkochen, is wholly owned by the Carl Zeiss Foundation.

For further information see: http://www.medit
'/>"/>

SOURCE Carl Zeiss Meditec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2015)... July 4, 2015 Adding ... patients with unresectable metastatic colorectal cancer in the ... organ Patients with unresectable metastatic colorectal ... liver experienced the greatest improvement in Progression-Free Survival ... SIR-Spheres Y-90 resin microspheres to a current first-line ...
(Date:7/3/2015)... , July 3, 2015 ... "Cardiac Monitoring & Cardiac Rhythm Management Market ECG, ... Monitoring, Defibrillator, Implantable Cardioverter Defibrillator, Dual Chamber Pacemaker, ... by MarketsandMarkets, the global Cardiac Monitoring (CM) and ... to reach $26,646.5 Million by 2020 from $21,137.7 ...
(Date:7/3/2015)... July 3, 2015 ... vorbehaltlich bestimmter Abschlussbedingungen eine 100-prozentige Beteiligung am ... haben. Mit dieser Übernahme dringt Lupin in ... Umsatz von 765 Mrd. RUB im Jahr ... Welt gehörte (IMS Health). Seit über einem ...
Breaking Medicine Technology:New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 2New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 4Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 2Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 4Lupin übernimmt Biocom aus Russland 2Lupin übernimmt Biocom aus Russland 3
... Chronic ... Hepatitis B-,-Studies will also Assess Clevudine,s Sustained Virologic Response Rate for ... HBV-, ... Phase 3 registration clinical trials,of clevudine for the treatment of chronic hepatitis B virus (HBV),infection. ...
... LOS ANGELES, Oct. 1 Signalife, Inc. (Amex:,SGN - ... and,technological evaluation of various new modules for its holter ... an important part of the,Company,s business plans and are ... FDA approval will now be made imminently in the,fourth ...
Cached Medicine Technology:Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 2Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 3Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 4Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 5Signalife Completes Testing of Modules for Holter and Intra-Cardiac Monitor 2
(Date:7/3/2015)... , ... July 03, 2015 ... ... the sessions and speaker lineup for its 2015 Annual Conference , ... August 6-8, 2015 at the Renaissance Orlando at SeaWorld in Orlando, Florida. ...
(Date:7/3/2015)... Buffalo, NY (PRWEB) , ... July 03, 2015 ... ... Noonday Learning Lecture took place on June 25, 2015 at 1:00pm. The Association ... presentation explored issues pertaining to injured bicyclists and practical points of investigating these ...
(Date:7/3/2015)... ... ... " Selfie on a Stick ” was featured on NewsWatch as part ... to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the ... , Almost every smartphone has an incredibly powerful camera built into it. And when ...
(Date:7/2/2015)... ... ... pleased to announce the opening of its newest location in Dallas, Texas. The opening is ... chain was listed as #22 on the Inc. 500 list of fastest growing companies in ... located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 , “We are excited ...
(Date:7/2/2015)... ... July 02, 2015 , ... Many Fourth of July celebrations ... why Amica Insurance is sharing some tips to promote the proper use ... people go to the emergency room daily with fireworks-related injuries in the month surrounding ...
Breaking Medicine News(10 mins):Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2Health News:6 Fireworks Safety Tips from Amica Insurance 2
... with distractions, study finds , MONDAY, April 26 (HealthDay ... or landing could lead to a critical error. Apparently ... administer medication to hospital patients. , A new ... patients, medication needs increases the chances of error. As ...
... team of researchers has pinpointed the location of bone generating ... and in other bones. The team also has identified ... was conducted at the National Institutes of Health and other ... some of the genetic triggers that control their growth is ...
... Minneapolis Heart Institute Foundation, Minneapolis Heart Institute at Abbott ... convening The Women and Heart Disease Summit in Minneapolis. ... honorary chair person; and co-chair people are Elizabeth Zane ... They will be joined by a faculty ...
... Society of Pediatric Otolaryngology (ASPO) will hold its annual ... Combined Otolaryngology Spring Meetings (COSM) - a joint meeting ... During the ASPO meeting, hundreds of pieces of ... panelists will be presented focusing on children,s ear, nose, ...
... Agency (EPA) Administrator Lisa P. Jackson and NASA ... science and engineering education at the Howard University ... The administrators chose the Howard University Middle ... and sciences among the next generation of leaders. ...
... --Race matters on a neurological level when it comes ... new Northwestern University study. In a rare neuroscience ... showed greater empathy for African-Americans facing adversity in ... Caucasians demonstrated for Caucasian-Americans in pain. "We ...
Cached Medicine News:Health News:Interrupting a Nurse Makes Medication Errors More Likely 2Health News:Interrupting a Nurse Makes Medication Errors More Likely 3Health News:Interrupting a Nurse Makes Medication Errors More Likely 4Health News:NIH study confirms location of stem cells near cartilage-rich regions in bones 2Health News:NIH study confirms location of stem cells near cartilage-rich regions in bones 3Health News:Scientific meeting will host new research in children's ear, nose and throat health 2Health News:EPA and NASA administrators to extend environmental and Earth science agreement 2Health News:Race and empathy matter on neural level 2
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
The D-Stat Radial hemostat band utilizes a compression band together with the active haemostatic material of the D-Stat to control surface bleeding....
The Prostar XL 8 is a suture mediated closure system. It can be used with 8F sheath. It has two 3-0 braided polyester sutures and also has the safety of guidewire....
... vascular closure device quickly seals ... procedures, allowing for early ambulation ... creates a mechanical seal by ... bio-absorbable anchor and collagen sponge, ...
Medicine Products: